Based on the human Expressed Sequence Tag (EST) data and The Cancer Genome Atlas (TCGA) data, RMEL3 was identified as a lncRNA with a specific and increased expression in melanoma compared with normal tissues and melanocytes.[50, 51] A positive correlation between RMEL3 expression and the presence of the BRAFV600E mutation was reported.[50] RMEL3 knockdown in melanoma cells of the A375-SM cell line resulted in the inactivation of the critical MAPK and PI3K signaling pathways.[51] BANCR and RMEL3 are two lncRNAs that seem to exert their effect through the MAPK pathway. This evidence concerns the gene BANCR and melanoma.